About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Non Muscle Invasive Bladder Cancer Pipeline Insight Report 2025 | Phase III Clinical Trials - Promising New Drug Developments - ResearchAndMarkets.com

The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.

The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" report provides a thorough examination of the pipeline landscape for Non Muscle Invasive Bladder Cancer (NMIBC), engaging with over 20 companies and 22 plus pipeline drugs. This report details both clinical and non-clinical stage products, offering insights into therapeutic assessments by product type, stage, and route of administration. Pipeline inactivity is also highlighted.

Non-muscle invasive bladder cancer remains predominantly confined to the bladder wall's inner layers, manifesting in stages such as Ta, T1, and carcinoma in situ (CIS). It represents about 70-80% of newly diagnosed cases with a high recurrence rate but lower progression risk. Essential management strategies include TURBT followed by intravesical therapies. Regular cystoscopic surveillance is crucial due to high recurrence probabilities.

Therapeutics in development are pioneering novel treatment prospects. Cretostimogene grenadenorepvec from CG Oncology is an oncolytic immunotherapy in Phase III, focusing on tumor-selective replication and immune response amplification. TAR-210 by Janssen Research & Development offers an innovative drug delivery system targeting FGFR alterations. In Phase II, Tyra Biosciences' TYRA-300 is assessed as an FGFR3-selective inhibitor. UGN-301, from UroGen Pharma Ltd., is an anti-CTLA-4 monoclonal antibody explored in a Phase I study for its effectiveness in maintaining local drug concentrations with reduced systemic exposure.

A comprehensive therapeutic assessment provided in the report classifies drugs by development stages: Phase III, II, I, Preclinical, and Discovery. Various routes of administration such as oral, intravenous, and intravesical are considered, alongside molecule types like small molecules, monoclonal antibodies, and gene therapies.

The report identifies significant players like CG Oncology and Tyra Biosciences, and delves into their pipeline activities, including collaborations, mergers, and licensing. Novel developments like small, bladder-resident devices or selective inhibitors show promising management avenues for NMIBC, especially for patients resistant to traditional therapies like BCG.

A detailed analysis covers emerging drugs, their clinical trial stages, and innovative pharmacological actions. This report highlights unmet needs, advances in drug types, and key designations granted to emerging therapies, positioning it as an essential resource for stakeholders aiming to navigate NMIBC treatment breakthroughs.

For further exploration and insights into NMIBC's therapeutic landscape, major players such as CG Oncology, Janssen Research & Development, Tyra Biosciences, UroGen Pharma, and others continue to drive the R&D sphere, adapting strategic measures to improve treatment efficacy and patient outcomes by 2025.

Key Topics Covered:

Introduction

Executive Summary

Non Muscle Invasive Bladder Cancer: Overview

  • Introduction
  • Causes
  • Pathophysiology
  • Signs and Symptoms
  • Diagnosis
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Non Muscle Invasive Bladder Cancer - Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Cretostimogene grenadenorepvec: CG Oncology

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

TYRA-300: Tyra Biosciences, Inc

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)

  • Comparative Analysis

UGN-301: UroGen Pharma Ltd.

  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

  • Comparative Analysis

Non Muscle Invasive Bladder Cancer Key Companies

Non Muscle Invasive Bladder Cancer Key Products

Non Muscle Invasive Bladder Cancer - Unmet Needs

Non Muscle Invasive Bladder Cancer - Market Drivers and Barriers

Non Muscle Invasive Bladder Cancer - Future Perspectives and Conclusion

Non Muscle Invasive Bladder Cancer Analyst Views

Non Muscle Invasive Bladder Cancer Key Companies

  • CG Oncology
  • Janssen Research & Development, LLC
  • Tyra Biosciences, Inc
  • UroGen Pharma Ltd.
  • Prokarium Ltd
  • Protara Therapeutics
  • ImmVira Pharma Co. Ltd
  • Trigone Pharma Ltd.
  • Hoffmann-La Roche
  • Aura Biosciences
  • enGene Holdings Inc.
  • Atonco Pharma

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/78gzrj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.